Adamis Pharmaceuticals Corporation

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)  is a specialty biopharmaceuticals company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI™ (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.  https://www.adamispharmaceuticals.com/social-media/

Sign up for free to view info

Email Format Employee directory